| Title： | Expert consensus on rational use of liver-protecting drugs in China(2023 version) |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Treatment |
| Countries and regions： | China |
| Guidelines users： | Clinical physicians at all levels (medicine, pharmacy, and other relevant fields) |
| Evidence classification method： | international evidence grading system |
| Development unit： | Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University |
| Registration time: | 2023-07-16 |
| Registration number： | PREPARE-2023CN511 |
| Purpose of the guideline: | Liver-protecting drugs possess diverse characteristics, including liver protection, promotion of liver cell regeneration, enhancement of liver detoxification, and immune response. Currently, there are various types of liver-protecting drugs available. However, controversies surrounding the use and administration of these drugs persist both domestically and internationally. One significant issue revolves around the lack of unified standards, particularly regarding drug selection and treatment duration. This lack of standardization increases the potential for irrational drug use, leading to adverse reactions, liver organ failure, and even death. To address this, extensive discussions and literature reviews were conducted on evidence-based medicine concerning the clinical application of liver-protecting drugs, resulting in the development of this consensus. |
Latest registration
